Evidence map›Paper›PMID 36831785›Full record

ReviewBrain sciences2023

New Insights into Potential Biomarkers in Patients with Mild Cognitive Impairment Occurring in the Prodromal Stage of Dementia with Lewy Bodies.

Niels Hansen, Caroline Bouter, Sebastian Johannes Müller, Christoph van Riesen, Eya Khadhraoui, Marielle Ernst, Christian Heiner Riedel, Jens Wiltfang, Claudia Lange

Abstract readReview
In one paragraph

Review in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  5. Review
  6. Mild cognitive impairment in dementia with Lewy bodies: an update and outlook.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Niels HansenDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen, 37075 Göttingen, Germany.
Caroline BouterDepartment of Nuclear Medicine, University Medical Center Göttingen, 37075 Göttingen, Germany.
Sebastian Johannes MüllerInstitute of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0003-2147-9797
Christoph van RiesenDepartment of Neurology, University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0003-1734-2421
Eya KhadhraouiInstitute of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0002-5433-1572
Marielle ErnstInstitute of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Christian Heiner RiedelInstitute of Diagnostic and Interventional Neuroradiology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen, 37075 Göttingen, Germany.
Claudia LangeDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen, 37075 Göttingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProdromal dementia with Lewy bodies (DLB) can emerge with the onset of mild cognitive impairment (MCI). Standard biomarkers can help identify such patients to improve therapy and treatment strategies. Our review aims to describe the latest evidence on promising biomarkers in prodromal DLB with MCI onset (MCI-LB).

methodsWe selected articles on different biomarkers in MCI-LB from PubMed and conducted a narrative review.

resultsWe identified potentially promising clinical biomarkers, e.g., (1) assessing autonomic symptoms specifically, (2) describing the cognitive profile in several subdomains including executive and visual functions, and (3) measuring the speed of speech. In addition, we describe the measurement of seeding amplification assays of alpha-synuclein in cerebrospinal fluid as a relevant biomarker for MCI-LB. Electroencephalographic markers, as in calculating the theta/beta ratio or intermittent delta activity, or analyzing peak frequency in electroencephalography-methods also potentially useful once they have been validated in large patient cohorts. The 18F fluorodesoxyglucose positron emission tomography (FDG-PET) technique is also discussed to investigate metabolic signatures, as well as a specific magnetic resonance imaging (MRI) technique such as for the volumetric region of interest analysis.

conclusionsThese biomarker results suggest that MCI-LB is a promising field for the use of biomarkers other than established ones to diagnose early prodromal DLB. Further large-scale studies are needed to better evaluate and subsequently use these promising biomarkers in prodromal DLB.

Indexed as

biomarkerneuroimagingprodromal dementia with Lewy bodiespsychiatry

Identifiers

PMID36831785
PMCPMC9953759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.